GURUFOCUS.COM » STOCK LIST » USA » NYSE » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Debt-to-EBITDA
Switch to:

Nuvation Bio Debt-to-EBITDA

: -0.03 (As of Jun. 2022)
View and export this data going back to 2021. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nuvation Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $0.94 Mil. Nuvation Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $3.75 Mil. Nuvation Bio's annualized EBITDA for the quarter that ended in Jun. 2022 was $-151.29 Mil. Nuvation Bio's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was -0.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Nuvation Bio's Debt-to-EBITDA or its related term are showing as below:

NUVB.WS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.04   Med: -0.03   Max: -0.03
Current: -0.04

During the past 2 years, the highest Debt-to-EBITDA Ratio of Nuvation Bio was -0.03. The lowest was -0.04. And the median was -0.03.

NUVB.WS's Debt-to-EBITDA is ranked worse than
100% of 298 companies
in the Biotechnology industry
Industry Median: 0.84 vs NUVB.WS: -0.04

Nuvation Bio Debt-to-EBITDA Historical Data

The historical data trend for Nuvation Bio's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Annual Data
Trend Dec20 Dec21
Debt-to-EBITDA
- -0.03

Nuvation Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.03 -0.03 -0.03

Competitive Comparison

For the Biotechnology subindustry, Nuvation Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Nuvation Bio Debt-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Nuvation Bio's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's Debt-to-EBITDA falls into.



Nuvation Bio Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nuvation Bio's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.863 + 2.192) / -93.134
=-0.03

Nuvation Bio's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.941 + 3.752) / -151.288
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2022) EBITDA data.


Nuvation Bio  (NYSE:NUVB.WS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Nuvation Bio Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvation Bio Business Description

Nuvation Bio logo
Traded in Other Exchanges
Address
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)